0001181431-11-054319.txt : 20111102
0001181431-11-054319.hdr.sgml : 20111102
20111102161459
ACCESSION NUMBER: 0001181431-11-054319
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20111101
FILED AS OF DATE: 20111102
DATE AS OF CHANGE: 20111102
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Johnston David Brannon
CENTRAL INDEX KEY: 0001486519
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34655
FILM NUMBER: 111174625
MAIL ADDRESS:
STREET 1: AVEO PHARMACEUTICALS, INC.
STREET 2: 75 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AVEO PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001325879
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 75 SIDNEY STREET
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6172995000
MAIL ADDRESS:
STREET 1: 75 SIDNEY STREET
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
rrd324723.xml
X0304
4
2011-11-01
0
0001325879
AVEO PHARMACEUTICALS INC
AVEO
0001486519
Johnston David Brannon
C/O AVEO PHARMACEUTICALS, INC.
75 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
Chief Financial Officer
Common Stock
2011-11-01
4
M
0
2000
5.60
A
8000
D
Common Stock
2011-11-01
4
S
0
2000
15.4390
D
6000
D
Employee Stock Option (right-to-buy)
5.60
2011-11-01
4
M
0
2000
0
D
2017-10-31
Common Stock
2000
166000
D
The exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2011.
The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.32 to $15.50, inclusive. The reporting person undertakes to provide AVEO Pharmaceuticals, Inc., any security holder of AVEO Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
The option vested as to 25% of the shares on October 31, 2008 and as to an additional 1/48 of the shares per month thereafter.
/s/ Joseph D. Vittiglio, Esq., attorney-in-fact
2011-11-02